Miruvor
Sign up
The short answer

What studies of Remdesivir (Veklury) found

28papers on Remdesivir (Veklury)
6,037people in 10 studies testing Remdesivir (Veklury) alone, and 17,164 patients in 1 health-record study, counted apart
3randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 4 findings, all C.

4 outcomes rated · see each below

Preventing long COVID: D Little or no difference

Based on the strongest evidence, compared with another group, not randomised and the randomised trial and randomised trials (very low certainty): 11 of 16 findings are D.

11 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: For long COVID, Remdesivir (Veklury) might help some people, but research can’t show it yet. For preventing long COVID, studies found little or no difference with Remdesivir (Veklury). If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 28 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Remdesivir (Veklury) · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Remdesivir (Veklury) · Preventing long COVID is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Anxiety1 study · 70 people took Remdesivir (Veklury) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.

Studies with no comparison group73 in the study · 70 with outcome data · five consecutive days · 200 mg loading dose on day 1; 100 mg on days 2–5, five consecutive days

Anxiety improved.

The evidence is very uncertain about the effect of remdesivir (Veklury) on anxiety in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
See the 1 study
  1. An open-label feasibility study of remdesivir in long COVID: results from the ERASE LC trial. (2026)

    People in the study
    73 in the study · 70 with outcome data
    Dose
    200 mg loading dose on day 1; 100 mg on days 2–5, five consecutive days
    Outcome
    GAD-7 moderate or severe anxiety generalized anxiety disorder questionnaire
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 70 people took Remdesivir (Veklury) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.

Studies with no comparison group73 in the study · 70 with outcome data · five consecutive days · 200 mg loading dose on day 1; 100 mg on days 2–5, five consecutive days

Fatigue improved.

The evidence is very uncertain about the effect of remdesivir (Veklury) on fatigue in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
See the 1 study
  1. An open-label feasibility study of remdesivir in long COVID: results from the ERASE LC trial. (2026)

    People in the study
    73 in the study · 70 with outcome data
    Dose
    200 mg loading dose on day 1; 100 mg on days 2–5, five consecutive days
    Outcome
    FAS total score Fatigue Assessment Scale
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Daily functioning1 study · 70 people took Remdesivir (Veklury) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.

Studies with no comparison group73 in the study · 70 with outcome data · five consecutive days · 200 mg loading dose on day 1; 100 mg on days 2–5, five consecutive days

Daily functioning improved.

The evidence is very uncertain about the effect of remdesivir (Veklury) on daily functioning in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
See the 1 study
  1. An open-label feasibility study of remdesivir in long COVID: results from the ERASE LC trial. (2026)

    People in the study
    73 in the study · 70 with outcome data
    Dose
    200 mg loading dose on day 1; 100 mg on days 2–5, five consecutive days
    Outcome
    Post-COVID-19 functional status category Post-COVID Functional Status scale
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Quality of life1 study · 70 people took Remdesivir (Veklury) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.

Studies with no comparison group73 in the study · 70 with outcome data · five consecutive days · 200 mg loading dose on day 1; 100 mg on days 2–5, five consecutive days

Quality of life improved.

The evidence is very uncertain about the effect of remdesivir (Veklury) on quality of life in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
See the 1 study
  1. An open-label feasibility study of remdesivir in long COVID: results from the ERASE LC trial. (2026)

    People in the study
    73 in the study · 70 with outcome data
    Dose
    200 mg loading dose on day 1; 100 mg on days 2–5, five consecutive days
    Outcome
    EQ-5D visual analogue score (VAS) EQ-5D visual analogue score
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Preventing long COVID

Symptoms

Cognition (brain fog)2 studies · 22,053 people took Remdesivir (Veklury) Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); not all results were tested against chance; the studies disagree; controlled studies found mixed results.

Compared with another group, not randomised2 studies · 52,036 people with results

Studies disagree about cognition (brain fog).

Studies disagree about whether remdesivir (Veklury) helps cognition (brain fog). Mixed results · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • Not all results were tested against chance
  • The studies disagree
See the 2 studies
  1. Risk of Long COVID in hospitalized individuals treated with remdesivir for acute COVID-19. (2025)

    People in the study
    52,006 in the study
    Dose
    Day 0 or Day 1
    Outcome
    cognitive dysfunction
    Effect
    better (not tested)
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: baseline characteristics, censoring, and competing risks weights derived from inverse probability weighting based on a propensity score for baseline characteristics, censoring, and competing risks
    Selection of participants
    Moderate. comparison group: unexposed comparator group included patients with no evidence of remdesivir use during the first 2 days of hospitalization the unexposed comparator group included patients with no evidence of remdesivir use during the first 2 days of hospitalization
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Patients who were censored or had evidence of inpatient mortality contributed to weighting models but were not included in the outcome models; thus, the number of patients contributing to each model varied. Patients who were censored or had evidence of inpatient mortality contributed to weighting models but were not included in the outcome models; thus, the number of patients contributing to each model varied.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome
  2. Remdesivir and risk of long-term multi-systemic sequelae following COVID-19 hospitalization. (2025)

    People in the study
    46 in the study · 30 started · 30 with outcome data
    Dose
    —
    Outcome
    Memory problems
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, ethnicity, housing type, vaccination status, comorbidities, immunocompromise, previous health care utilization, supplementary oxygen, ICU admission, concurrent steroids Regression adjusted based on demographic characteristics (age, sex, and ethnicity), socioeconomic status (housing type), vaccination status, comorbidities, immunocompromise, previous health care utilization, and severity of initial infection
    Selection of participants
    Moderate. comparison group: Untreated hospitalized COVID-19 cases meeting the same remdesivir indication criteria, balanced by overlap weighting using untreated hospitalized COVID-19 cases as a comparator
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Exclusions before analysis: "Individuals who died ≤30 days or who were reinfected within 300 days of hospitalization were additionally excluded."; no per-arm missing-data counts reported. Individuals who died ≤30 days or who were reinfected within 300 days of hospitalization were additionally excluded.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome
Sleep4 studies · 661 people took Remdesivir (Veklury) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); not all results were tested against chance; the studies disagree.

Compared with another group, not randomised4 studies · 870 people with results

Sleep improved more than in the comparison group.

The evidence is very uncertain about the effect of remdesivir (Veklury) on sleep later, when given during acute COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • Not all results were tested against chance
  • The studies disagree
See the 4 studies
  1. Real-world evidence of remdesivir in formerly hospitalized COVID-19 patients: patient-reported and functional outcomes. (2025)

    People in the study
    293 in the study · 94 with outcome data
    Dose
    —
    Outcome
    PSQI score Pittsburg Sleep Quality Index
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: Propensity score matched 1:1 using 16 criteria age, sex, Body-Mass Index (BMI), VOC, chronic obstructive pulmonary disease (COPD), asthma, diabetes, coronary artery disease (CAD), chronic heart failure (CHF), peripheral artery disease (PAD), Stroke/TIA, Charlson Comorbidity Index
    Selection of participants
    Moderate. comparison group: Propensity score matched 1:1 using 16 criteria Propensity score matching (PSM) was used (16 criteria, 1:1 ratio) to obtain two comparable groups
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Exclusion criteria included chronic kidney disease, liver disease, loss to follow-up, unavailable/inconsistent data; per-arm missing not reported Exclusion criteria for this study included chronic kidney disease; liver disease; loss to follow-up; and unavailable or inconsistent data regarding hospitalization
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome
  2. Intravenous Administration of Remdesivir at the Acute Phase of SARS-CoV-2 Infection Is Associated with a Lower Prevalence of Post-COVID-19 Pain. (2025)

    People in the study
    300 in the study · 216 with outcome data
    Dose
    an initial dose of 200 mg on the first day, followed by 100 mg per day, 200 mg on the first day, followed by 100 mg per day for five consecutive days or until discharge if the hospitalization period was shorter than five days, with a maximum treatment duration of 10 days
    Outcome
    poor sleep quality Pittsburgh Sleep Quality Index (PSQI)
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: Matched to the Remdesivir cohort on age, sex, body mass index and vaccination status adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated through multivariate logistic regression models with all pre-existing conditions included into the analysis
    Selection of participants
    Moderate. comparison group: Matched to the Remdesivir cohort on age, sex, body mass index and vaccination status These individuals were matched with the first cohort based on age, sex, body mass index, and vaccination status
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Of 300 invited Remdesivir patients, 216 agreed to take part; handling of non-participants not described A total of 300 previously hospitalized patients (75 randomly selected from each hospital) who had received intravenous Remdesivir during the acute phase of infection were invited to participate.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  3. Formerly hospitalized patients treated with remdesivir presented less respiratory post-COVID symptoms (2023)

    People in the study
    267 in the study
    Dose
    —
    Outcome
    sleep disorders
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: Patients were divided according receiving remdesivir (RDV; N=168) or standard of care (SOC; N=99). Patients were divided according receiving remdesivir (RDV; N=168) or standard of care (SOC; N=99).
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  4. Better post-acute sequelae COVID19 observed in hospitalized COVID19 patients treated with remdesivir (2024)

    People in the study
    293 in the study
    Dose
    —
    Outcome
    sleep disturbances
    Effect
    better (not tested)
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: categorized based on receiving RDV or only standard of care (SOC) categorized based on receiving RDV (N=183) or only standard of care (SOC; N=110)
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Low mood or anxiety2 studies · 258 people took Remdesivir (Veklury) Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); randomised trials found little or no difference.

The randomised trial185 randomised · 118 started · 118 analysed · 1 and 3 months after randomisation

No clear difference in low mood or anxiety.

The evidence is very uncertain about the effect of remdesivir (Veklury) on low mood or anxiety later, when given during acute COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 118 people found no clear difference; a small benefit can't be ruled out

Compared with another group, not randomised300 in the study · 216 with outcome data · Remdesivir group 18.3 months (SD: 0.7) post-hospitalization; non-antiviral group 18.4 months (SD: 1.0); abstract: mean follow-up 18.4, SD 0.8 months · an initial dose of 200 mg on the first day, followed by 100 mg per day, 200 mg on the first day, followed by 100 mg per day for five consecutive days or until discharge if the hospitalization period was shorter than five days, with a maximum treatment duration of 10 days

Low mood or anxiety improved more than in the comparison group.

The evidence is very uncertain about the effect of remdesivir (Veklury) on low mood or anxiety later, when given during acute COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
See the 2 studies
  1. The effects of remdesivir on long-term symptoms in patients hospitalised for COVID-19: a pre-specified exploratory analysis (2024)

    People in the study
    185 randomised · 118 started · 118 analysed
    Dose
    —
    Outcome
    Role limitations due to emotional problems RAND 36-item health survey (SF-36)
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  2. Intravenous Administration of Remdesivir at the Acute Phase of SARS-CoV-2 Infection Is Associated with a Lower Prevalence of Post-COVID-19 Pain. (2025)

    People in the study
    300 in the study · 216 with outcome data
    Dose
    an initial dose of 200 mg on the first day, followed by 100 mg per day, 200 mg on the first day, followed by 100 mg per day for five consecutive days or until discharge if the hospitalization period was shorter than five days, with a maximum treatment duration of 10 days
    Outcome
    anxiety Hospital Anxiety and Depression Scale (HADS)
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: Matched to the Remdesivir cohort on age, sex, body mass index and vaccination status adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated through multivariate logistic regression models with all pre-existing conditions included into the analysis
    Selection of participants
    Moderate. comparison group: Matched to the Remdesivir cohort on age, sex, body mass index and vaccination status These individuals were matched with the first cohort based on age, sex, body mass index, and vaccination status
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Of 300 invited Remdesivir patients, 216 agreed to take part; handling of non-participants not described A total of 300 previously hospitalized patients (75 randomly selected from each hospital) who had received intravenous Remdesivir during the acute phase of infection were invited to participate.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Breathlessness5 studies · 22,498 people took Remdesivir (Veklury) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance; the studies disagree; effect size 0.00 (very small).

Compared with another group, not randomised5 studies · 52,690 people with results

No clear difference in breathlessness.

The evidence is very uncertain about the effect of remdesivir (Veklury) on breathlessness later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
  • The studies disagree
  • Effect size 0.00 (very small)

How big was the difference?

0, very small. The effect size compares Remdesivir (Veklury) with unexposed.

See the 5 studies
  1. Risk of Long COVID in hospitalized individuals treated with remdesivir for acute COVID-19. (2025)

    People in the study
    52,006 in the study
    Dose
    Day 0 or Day 1
    Outcome
    dyspnea/breathlessness
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: baseline characteristics, censoring, and competing risks weights derived from inverse probability weighting based on a propensity score for baseline characteristics, censoring, and competing risks
    Selection of participants
    Moderate. comparison group: unexposed comparator group included patients with no evidence of remdesivir use during the first 2 days of hospitalization the unexposed comparator group included patients with no evidence of remdesivir use during the first 2 days of hospitalization
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Patients who were censored or had evidence of inpatient mortality contributed to weighting models but were not included in the outcome models; thus, the number of patients contributing to each model varied. Patients who were censored or had evidence of inpatient mortality contributed to weighting models but were not included in the outcome models; thus, the number of patients contributing to each model varied.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome
  2. Real-world evidence of remdesivir in formerly hospitalized COVID-19 patients: patient-reported and functional outcomes. (2025)

    People in the study
    293 in the study · 94 with outcome data
    Dose
    —
    Outcome
    PF tests
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: No information
    Confounding
    Moderate. comparison group: Propensity score matched 1:1 using 16 criteria age, sex, Body-Mass Index (BMI), VOC, chronic obstructive pulmonary disease (COPD), asthma, diabetes, coronary artery disease (CAD), chronic heart failure (CHF), peripheral artery disease (PAD), Stroke/TIA, Charlson Comorbidity Index
    Selection of participants
    Moderate. comparison group: Propensity score matched 1:1 using 16 criteria Propensity score matching (PSM) was used (16 criteria, 1:1 ratio) to obtain two comparable groups
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Exclusion criteria included chronic kidney disease, liver disease, loss to follow-up, unavailable/inconsistent data; per-arm missing not reported Exclusion criteria for this study included chronic kidney disease; liver disease; loss to follow-up; and unavailable or inconsistent data regarding hospitalization
    Measurement of outcomes
    Moderate. administered or clinician-rated; assessors blinded: NI
    Selection of the reported result
    Moderate. a pre-specified secondary outcome
  3. Remdesivir and risk of long-term multi-systemic sequelae following COVID-19 hospitalization. (2025)

    People in the study
    46 in the study · 30 started · 30 with outcome data
    Dose
    —
    Outcome
    Dyspnoea
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, ethnicity, housing type, vaccination status, comorbidities, immunocompromise, previous health care utilization, supplementary oxygen, ICU admission, concurrent steroids Regression adjusted based on demographic characteristics (age, sex, and ethnicity), socioeconomic status (housing type), vaccination status, comorbidities, immunocompromise, previous health care utilization, and severity of initial infection
    Selection of participants
    Moderate. comparison group: Untreated hospitalized COVID-19 cases meeting the same remdesivir indication criteria, balanced by overlap weighting using untreated hospitalized COVID-19 cases as a comparator
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Exclusions before analysis: "Individuals who died ≤30 days or who were reinfected within 300 days of hospitalization were additionally excluded."; no per-arm missing-data counts reported. Individuals who died ≤30 days or who were reinfected within 300 days of hospitalization were additionally excluded.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome
  4. Formerly hospitalized patients treated with remdesivir presented less respiratory post-COVID symptoms (2023)

    People in the study
    267 in the study
    Dose
    —
    Outcome
    respiratory
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: Patients were divided according receiving remdesivir (RDV; N=168) or standard of care (SOC; N=99). Patients were divided according receiving remdesivir (RDV; N=168) or standard of care (SOC; N=99).
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  5. Better post-acute sequelae COVID19 observed in hospitalized COVID19 patients treated with remdesivir (2024)

    People in the study
    293 in the study
    Dose
    —
    Outcome
    PF
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: No information
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: categorized based on receiving RDV or only standard of care (SOC) categorized based on receiving RDV (N=183) or only standard of care (SOC; N=110)
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Moderate. administered or clinician-rated; assessors blinded: NI
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Pain4 studies · 22,311 people took Remdesivir (Veklury) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 118 people found no clear difference; a small benefit can't be ruled out.

The randomised trial185 randomised · 118 started · 118 analysed · 1 and 3 months after randomisation

No clear difference in pain.

The evidence is very uncertain about the effect of remdesivir (Veklury) on pain later, when given during acute COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 118 people found no clear difference; a small benefit can't be ruled out

Compared with another group, not randomised3 studies · 52,252 people with results

No clear difference in pain.

The evidence is very uncertain about the effect of remdesivir (Veklury) on pain later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
  • The studies disagree
  • Effect size 0.00 (very small)

How big was the difference?

0, very small. The effect size compares Remdesivir (Veklury) with previously hospitalized covid-19 survivors who did not receive any antiviral treatment during the acute infection phase at hospitalization.

See the 4 studies
  1. The effects of remdesivir on long-term symptoms in patients hospitalised for COVID-19: a pre-specified exploratory analysis (2024)

    People in the study
    185 randomised · 118 started · 118 analysed
    Dose
    —
    Outcome
    Bodily pain RAND 36-item health survey (SF-36)
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  2. Intravenous Administration of Remdesivir at the Acute Phase of SARS-CoV-2 Infection Is Associated with a Lower Prevalence of Post-COVID-19 Pain. (2025)

    People in the study
    300 in the study · 216 with outcome data
    Dose
    an initial dose of 200 mg on the first day, followed by 100 mg per day, 200 mg on the first day, followed by 100 mg per day for five consecutive days or until discharge if the hospitalization period was shorter than five days, with a maximum treatment duration of 10 days
    Outcome
    overall post-COVID-19 pain
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: Matched to the Remdesivir cohort on age, sex, body mass index and vaccination status adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated through multivariate logistic regression models with all pre-existing conditions included into the analysis
    Selection of participants
    Moderate. comparison group: Matched to the Remdesivir cohort on age, sex, body mass index and vaccination status These individuals were matched with the first cohort based on age, sex, body mass index, and vaccination status
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Of 300 invited Remdesivir patients, 216 agreed to take part; handling of non-participants not described A total of 300 previously hospitalized patients (75 randomly selected from each hospital) who had received intravenous Remdesivir during the acute phase of infection were invited to participate.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified primary outcome
  3. Risk of Long COVID in hospitalized individuals treated with remdesivir for acute COVID-19. (2025)

    People in the study
    52,006 in the study
    Dose
    Day 0 or Day 1
    Outcome
    joint pain/arthralgia
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: baseline characteristics, censoring, and competing risks weights derived from inverse probability weighting based on a propensity score for baseline characteristics, censoring, and competing risks
    Selection of participants
    Moderate. comparison group: unexposed comparator group included patients with no evidence of remdesivir use during the first 2 days of hospitalization the unexposed comparator group included patients with no evidence of remdesivir use during the first 2 days of hospitalization
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Patients who were censored or had evidence of inpatient mortality contributed to weighting models but were not included in the outcome models; thus, the number of patients contributing to each model varied. Patients who were censored or had evidence of inpatient mortality contributed to weighting models but were not included in the outcome models; thus, the number of patients contributing to each model varied.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome
  4. Remdesivir and risk of long-term multi-systemic sequelae following COVID-19 hospitalization. (2025)

    People in the study
    46 in the study · 30 started · 30 with outcome data
    Dose
    —
    Outcome
    Chest pain
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, ethnicity, housing type, vaccination status, comorbidities, immunocompromise, previous health care utilization, supplementary oxygen, ICU admission, concurrent steroids Regression adjusted based on demographic characteristics (age, sex, and ethnicity), socioeconomic status (housing type), vaccination status, comorbidities, immunocompromise, previous health care utilization, and severity of initial infection
    Selection of participants
    Moderate. comparison group: Untreated hospitalized COVID-19 cases meeting the same remdesivir indication criteria, balanced by overlap weighting using untreated hospitalized COVID-19 cases as a comparator
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Exclusions before analysis: "Individuals who died ≤30 days or who were reinfected within 300 days of hospitalization were additionally excluded."; no per-arm missing-data counts reported. Individuals who died ≤30 days or who were reinfected within 300 days of hospitalization were additionally excluded.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome
Fatigue4 studies · 22,263 people took Remdesivir (Veklury) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 118 people found no clear difference; a small benefit can't be ruled out.

The randomised trial185 randomised · 118 started · 118 analysed · 1 and 3 months after randomisation

No clear difference in fatigue.

The evidence is very uncertain about the effect of remdesivir (Veklury) on fatigue later, when given during acute COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 118 people found no clear difference; a small benefit can't be ruled out

Compared with another group, not randomised3 studies · 52,303 people with results

No clear difference in fatigue.

The evidence is very uncertain about the effect of remdesivir (Veklury) on fatigue later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
  • The studies disagree
  • Effect size 0.00 (very small)

How big was the difference?

0, very small. The effect size compares Remdesivir (Veklury) with unexposed.

See the 4 studies
  1. The effects of remdesivir on long-term symptoms in patients hospitalised for COVID-19: a pre-specified exploratory analysis (2024)

    People in the study
    185 randomised · 118 started · 118 analysed
    Dose
    —
    Outcome
    Energy/fatigue RAND 36-item health survey (SF-36)
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  2. Risk of Long COVID in hospitalized individuals treated with remdesivir for acute COVID-19. (2025)

    People in the study
    52,006 in the study
    Dose
    Day 0 or Day 1
    Outcome
    fatigue
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: baseline characteristics, censoring, and competing risks weights derived from inverse probability weighting based on a propensity score for baseline characteristics, censoring, and competing risks
    Selection of participants
    Moderate. comparison group: unexposed comparator group included patients with no evidence of remdesivir use during the first 2 days of hospitalization the unexposed comparator group included patients with no evidence of remdesivir use during the first 2 days of hospitalization
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Patients who were censored or had evidence of inpatient mortality contributed to weighting models but were not included in the outcome models; thus, the number of patients contributing to each model varied. Patients who were censored or had evidence of inpatient mortality contributed to weighting models but were not included in the outcome models; thus, the number of patients contributing to each model varied.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome
  3. Formerly hospitalized patients treated with remdesivir presented less respiratory post-COVID symptoms (2023)

    People in the study
    267 in the study
    Dose
    —
    Outcome
    fatigue
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: Patients were divided according receiving remdesivir (RDV; N=168) or standard of care (SOC; N=99). Patients were divided according receiving remdesivir (RDV; N=168) or standard of care (SOC; N=99).
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  4. Remdesivir and risk of long-term multi-systemic sequelae following COVID-19 hospitalization. (2025)

    People in the study
    46 in the study · 30 started · 30 with outcome data
    Dose
    —
    Outcome
    Fatigue
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, ethnicity, housing type, vaccination status, comorbidities, immunocompromise, previous health care utilization, supplementary oxygen, ICU admission, concurrent steroids Regression adjusted based on demographic characteristics (age, sex, and ethnicity), socioeconomic status (housing type), vaccination status, comorbidities, immunocompromise, previous health care utilization, and severity of initial infection
    Selection of participants
    Moderate. comparison group: Untreated hospitalized COVID-19 cases meeting the same remdesivir indication criteria, balanced by overlap weighting using untreated hospitalized COVID-19 cases as a comparator
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Exclusions before analysis: "Individuals who died ≤30 days or who were reinfected within 300 days of hospitalization were additionally excluded."; no per-arm missing-data counts reported. Individuals who died ≤30 days or who were reinfected within 300 days of hospitalization were additionally excluded.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome
Smell and taste loss1 study · 17,164 people took Remdesivir (Veklury) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised52,006 in the study · ≥1 dose on Day 0 or Day 1 · Day 0 or Day 1

No clear difference in smell and taste loss.

The evidence is very uncertain about the effect of remdesivir (Veklury) on smell and taste loss later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Risk of Long COVID in hospitalized individuals treated with remdesivir for acute COVID-19. (2025)

    People in the study
    52,006 in the study
    Dose
    Day 0 or Day 1
    Outcome
    taste disturbance/dysgeusia/ageusia
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: baseline characteristics, censoring, and competing risks weights derived from inverse probability weighting based on a propensity score for baseline characteristics, censoring, and competing risks
    Selection of participants
    Moderate. comparison group: unexposed comparator group included patients with no evidence of remdesivir use during the first 2 days of hospitalization the unexposed comparator group included patients with no evidence of remdesivir use during the first 2 days of hospitalization
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Patients who were censored or had evidence of inpatient mortality contributed to weighting models but were not included in the outcome models; thus, the number of patients contributing to each model varied. Patients who were censored or had evidence of inpatient mortality contributed to weighting models but were not included in the outcome models; thus, the number of patients contributing to each model varied.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome
Autonomic symptoms1 study · 4,889 people took Remdesivir (Veklury) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); few people (30 in all); effect size 0.00 (very small).

Compared with another group, not randomised46 in the study · 30 started · 30 with outcome data · 31—300 days post-T0 (mean 241.0 days remdesivir-treated; 256.9 days untreated)

No clear difference in autonomic symptoms.

The evidence is very uncertain about the effect of remdesivir (Veklury) on autonomic symptoms later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • Few people (30 in all)
  • Effect size 0.00 (very small)

How big was the difference?

0, very small. The effect size compares Remdesivir (Veklury) with controls (not treated with remdesivir).

See the 1 study
  1. Remdesivir and risk of long-term multi-systemic sequelae following COVID-19 hospitalization. (2025)

    People in the study
    46 in the study · 30 started · 30 with outcome data
    Dose
    —
    Outcome
    Palpitations
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, ethnicity, housing type, vaccination status, comorbidities, immunocompromise, previous health care utilization, supplementary oxygen, ICU admission, concurrent steroids Regression adjusted based on demographic characteristics (age, sex, and ethnicity), socioeconomic status (housing type), vaccination status, comorbidities, immunocompromise, previous health care utilization, and severity of initial infection
    Selection of participants
    Moderate. comparison group: Untreated hospitalized COVID-19 cases meeting the same remdesivir indication criteria, balanced by overlap weighting using untreated hospitalized COVID-19 cases as a comparator
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Exclusions before analysis: "Individuals who died ≤30 days or who were reinfected within 300 days of hospitalization were additionally excluded."; no per-arm missing-data counts reported. Individuals who died ≤30 days or who were reinfected within 300 days of hospitalization were additionally excluded.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome

Daily life and health overall

Overall symptoms8 studies · 22,747 people took Remdesivir (Veklury) Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the studies disagree; randomised trials found little or no difference.

Randomised trials3 studies · 480 people with results

No clear difference in overall symptoms.

The evidence is very uncertain about the effect of remdesivir (Veklury) on overall symptoms later, when given during acute COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • No confidence interval shows an important benefit is ruled out

Compared with another group, not randomised5 studies · 52,872 people with results

Overall symptoms improved more than in the comparison group.

The evidence is very uncertain about the effect of remdesivir (Veklury) on overall symptoms later, when given during acute COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • The studies disagree
See the 8 studies
  1. 1126. Effect of Remdesivir on Recovery, Quality of Life, and Long-COVID Symptoms One Year after Hospitalization for COVID-19 Infection: A Randomized Controlled SOLIDARITY Finland Trial (2022)

    People in the study
    208 randomised · 181 analysed
    Dose
    median durationofremdesivir treatment5 days
    Outcome
    overall mortality
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial. (2022)

    People in the study
    208 randomised · 181 analysed
    Dose
    200 mg on the first day and 100 mg per day, until discharge or for a maximum duration of 10 days
    Outcome
    Mortality at 1 year
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  3. The effects of remdesivir on long-term symptoms in patients hospitalised for COVID-19: a pre-specified exploratory analysis (2024)

    People in the study
    185 randomised · 118 started · 118 analysed
    Dose
    —
    Outcome
    General health perceptions RAND 36-item health survey (SF-36)
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  4. Real-world evidence of remdesivir in formerly hospitalized COVID-19 patients: patient-reported and functional outcomes. (2025)

    People in the study
    293 in the study · 94 with outcome data
    Dose
    —
    Outcome
    Asmyptomatic patients at 6 month following infection N (%)
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: Propensity score matched 1:1 using 16 criteria age, sex, Body-Mass Index (BMI), VOC, chronic obstructive pulmonary disease (COPD), asthma, diabetes, coronary artery disease (CAD), chronic heart failure (CHF), peripheral artery disease (PAD), Stroke/TIA, Charlson Comorbidity Index
    Selection of participants
    Moderate. comparison group: Propensity score matched 1:1 using 16 criteria Propensity score matching (PSM) was used (16 criteria, 1:1 ratio) to obtain two comparable groups
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Exclusion criteria included chronic kidney disease, liver disease, loss to follow-up, unavailable/inconsistent data; per-arm missing not reported Exclusion criteria for this study included chronic kidney disease; liver disease; loss to follow-up; and unavailable or inconsistent data regarding hospitalization
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified primary outcome
  5. Risk of Long COVID in hospitalized individuals treated with remdesivir for acute COVID-19. (2025)

    People in the study
    52,006 in the study
    Dose
    Day 0 or Day 1
    Outcome
    any Long COVID outcome
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: baseline characteristics, censoring, and competing risks weights derived from inverse probability weighting based on a propensity score for baseline characteristics, censoring, and competing risks
    Selection of participants
    Moderate. comparison group: unexposed comparator group included patients with no evidence of remdesivir use during the first 2 days of hospitalization the unexposed comparator group included patients with no evidence of remdesivir use during the first 2 days of hospitalization
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Patients who were censored or had evidence of inpatient mortality contributed to weighting models but were not included in the outcome models; thus, the number of patients contributing to each model varied. Patients who were censored or had evidence of inpatient mortality contributed to weighting models but were not included in the outcome models; thus, the number of patients contributing to each model varied.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified primary outcome
  6. Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect? (2022)

    People in the study
    462 in the study · 449 started · 449 with outcome data
    Dose
    —
    Outcome
    Independent predictor of LCS: treatment with remdesivir
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: principal baseline parameters; ICU admission, time of hospitalization, treatment with remdesivir in multivariate model After multivariate adjustment considering the principal baseline parameters, ICU admission (OR 1⁄4 2.551; 95% CI 1⁄4 1.998–6.819; P 1⁄4 0.019), time of hospitalization (OR 1⁄4 2.255; 95% CI 1⁄4 1.018–6.992; P 1⁄4 0.016) and treatment with remdesivir
    Selection of participants
    Moderate. comparison group: non-randomised; remdesivir available in Italy only from September 2020 under stated inclusion criteria, so earlier patients were untreated after September 2020 was approved in Italy the use of remdesivir according to the following inclusion criteria
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 14 patients (3.1%) excluded between Visit 1 and Visit 2: 2 died, 8 lost at follow-up, 4 re-hospitalized; a further 13 of 462 discharged patients not included Between the Visits 1 and 2, 14 patients (3.1%) were excluded for the following reasons: 2 died, 8 lost at the follow-up, 4 were re-hospitalized
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  7. Remdesivir and risk of long-term multi-systemic sequelae following COVID-19 hospitalization. (2025)

    People in the study
    46 in the study · 30 started · 30 with outcome data
    Dose
    —
    Outcome
    long-term symptom persistence
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, ethnicity, housing type, vaccination status, comorbidities, immunocompromise, previous health care utilization, supplementary oxygen, ICU admission, concurrent steroids Regression adjusted based on demographic characteristics (age, sex, and ethnicity), socioeconomic status (housing type), vaccination status, comorbidities, immunocompromise, previous health care utilization, and severity of initial infection
    Selection of participants
    Moderate. comparison group: Untreated hospitalized COVID-19 cases meeting the same remdesivir indication criteria, balanced by overlap weighting using untreated hospitalized COVID-19 cases as a comparator
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Exclusions before analysis: "Individuals who died ≤30 days or who were reinfected within 300 days of hospitalization were additionally excluded."; no per-arm missing-data counts reported. Individuals who died ≤30 days or who were reinfected within 300 days of hospitalization were additionally excluded.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome
  8. Better post-acute sequelae COVID19 observed in hospitalized COVID19 patients treated with remdesivir (2024)

    People in the study
    293 in the study
    Dose
    —
    Outcome
    PASC symptom profile
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: categorized based on receiving RDV or only standard of care (SOC) categorized based on receiving RDV (N=183) or only standard of care (SOC; N=110)
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Quality of life3 studies · 445 people took Remdesivir (Veklury) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the studies disagree.

Compared with another group, not randomised3 studies · 654 people with results

Quality of life improved more than in the comparison group.

The evidence is very uncertain about the effect of remdesivir (Veklury) on quality of life later, when given during acute COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • The studies disagree
See the 3 studies
  1. Real-world evidence of remdesivir in formerly hospitalized COVID-19 patients: patient-reported and functional outcomes. (2025)

    People in the study
    293 in the study · 94 with outcome data
    Dose
    —
    Outcome
    other QoL questionnaires
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: Propensity score matched 1:1 using 16 criteria age, sex, Body-Mass Index (BMI), VOC, chronic obstructive pulmonary disease (COPD), asthma, diabetes, coronary artery disease (CAD), chronic heart failure (CHF), peripheral artery disease (PAD), Stroke/TIA, Charlson Comorbidity Index
    Selection of participants
    Moderate. comparison group: Propensity score matched 1:1 using 16 criteria Propensity score matching (PSM) was used (16 criteria, 1:1 ratio) to obtain two comparable groups
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Exclusion criteria included chronic kidney disease, liver disease, loss to follow-up, unavailable/inconsistent data; per-arm missing not reported Exclusion criteria for this study included chronic kidney disease; liver disease; loss to follow-up; and unavailable or inconsistent data regarding hospitalization
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome
  2. Better post-acute sequelae COVID19 observed in hospitalized COVID19 patients treated with remdesivir (2024)

    People in the study
    293 in the study
    Dose
    —
    Outcome
    patient reported QoL
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: categorized based on receiving RDV or only standard of care (SOC) categorized based on receiving RDV (N=183) or only standard of care (SOC; N=110)
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  3. Formerly hospitalized patients treated with remdesivir presented less respiratory post-COVID symptoms (2023)

    People in the study
    267 in the study
    Dose
    —
    Outcome
    VAS visual analogue scale
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: Patients were divided according receiving remdesivir (RDV; N=168) or standard of care (SOC; N=99). Patients were divided according receiving remdesivir (RDV; N=168) or standard of care (SOC; N=99).
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Daily functioning4 studies · 556 people took Remdesivir (Veklury) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 118 people found no clear difference; a small benefit can't be ruled out.

The randomised trial185 randomised · 118 started · 118 analysed · 1 and 3 months after randomisation

No clear difference in daily functioning.

The evidence is very uncertain about the effect of remdesivir (Veklury) on daily functioning later, when given during acute COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 118 people found no clear difference; a small benefit can't be ruled out

Compared with another group, not randomised3 studies · 1,009 people with results

No clear difference in daily functioning.

The evidence is very uncertain about the effect of remdesivir (Veklury) on daily functioning later, when given during acute COVID. Little or no difference · very low certainty D

  • Risk of bias couldn't be judged for most results (ROBINS-I: no information)
  • The change wasn't shown to be more than chance
  • The studies disagree
See the 4 studies
  1. The effects of remdesivir on long-term symptoms in patients hospitalised for COVID-19: a pre-specified exploratory analysis (2024)

    People in the study
    185 randomised · 118 started · 118 analysed
    Dose
    —
    Outcome
    Physical functioning RAND 36-item health survey (SF-36)
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  2. Formerly hospitalized patients treated with remdesivir presented less respiratory post-COVID symptoms (2023)

    People in the study
    267 in the study
    Dose
    —
    Outcome
    Lung function and 6MWT values
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: No information
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: Patients were divided according receiving remdesivir (RDV; N=168) or standard of care (SOC; N=99). Patients were divided according receiving remdesivir (RDV; N=168) or standard of care (SOC; N=99).
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Moderate. administered or clinician-rated; assessors blinded: NI
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  3. Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect? (2022)

    People in the study
    462 in the study · 449 started · 449 with outcome data
    Dose
    —
    Outcome
    PCFS score between 2 and 3 at Visit 1 by remdesivir treatment post-COVID-19 functional status (PCFS) scale
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: principal baseline parameters; ICU admission, time of hospitalization, treatment with remdesivir in multivariate model After multivariate adjustment considering the principal baseline parameters, ICU admission (OR 1⁄4 2.551; 95% CI 1⁄4 1.998–6.819; P 1⁄4 0.019), time of hospitalization (OR 1⁄4 2.255; 95% CI 1⁄4 1.018–6.992; P 1⁄4 0.016) and treatment with remdesivir
    Selection of participants
    Moderate. comparison group: non-randomised; remdesivir available in Italy only from September 2020 under stated inclusion criteria, so earlier patients were untreated after September 2020 was approved in Italy the use of remdesivir according to the following inclusion criteria
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 14 patients (3.1%) excluded between Visit 1 and Visit 2: 2 died, 8 lost at follow-up, 4 re-hospitalized; a further 13 of 462 discharged patients not included Between the Visits 1 and 2, 14 patients (3.1%) were excluded for the following reasons: 2 died, 8 lost at the follow-up, 4 were re-hospitalized
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  4. Better post-acute sequelae COVID19 observed in hospitalized COVID19 patients treated with remdesivir (2024)

    People in the study
    293 in the study
    Dose
    —
    Outcome
    6MWT parameters 6-minute walk test
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: No information
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: categorized based on receiving RDV or only standard of care (SOC) categorized based on receiving RDV (N=183) or only standard of care (SOC; N=110)
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Moderate. administered or clinician-rated; assessors blinded: NI
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported

Side effects

Side effects studies reported4 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Fatigue1 study
Headache1 study
Nausea or stomach upset1 study
Worse symptoms or a flare1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    200 mg at the start in most studies

  2. 2Top dose

    Most often 200 mg (5 of 5 studies)

Doses across 5 studies

200 to 200 mg.

Each study’s dose, as printed

Systematic reviews

Reviews pool earlier studies. Each shows when it was published and how far its search went.

All papers

  1. The effects of remdesivir on long-term symptoms in patients hospitalised for COVID-19: a pre-specified exploratory analysis2024 · randomised trial · 185 randomised · 118 started · 118 analysed
    Summary

    This pre-specified exploratory analysis of the open-label randomised NOR-Solidarity trial asked whether remdesivir given during hospitalisation for COVID-19 affected long-term symptoms. The main trial included 185 patients; after exclusions, 118 patients were analysed: 42 randomised to standard of care plus remdesivir and 76 to a post-hoc control group of standard of care alone or with hydroxychloroquine (SoC ± HCQ). Treatment duration is not reported. Patients completed quality-of-life surveys at 1 and 3 months after randomisation; the primary outcomes were self-reported fatigue, shortness of breath and coughing at 3 months on the COPD Assessment Test, with total CAT, EQ-5D-5L and RAND SF-36 scores as secondary outcomes. At 3 months, the remdesivir group did not show significant improvements compared with controls: CAT fatigue mean 2.6 (SD 1.5) v 2.1 (1.6), p = 0.129; shortness of breath 3.0 (1.7) v 2.1 (1.8), p = 0.110; coughing 1.8 (1.6) v 1.2 (1.5), p = 0.237. Scores were numerically higher in the remdesivir group but the authors report no indication of harm. Harms and withdrawals due to harms are not reported; four randomised participants were excluded, one wrongly included and three who withdrew consent before treatment.

  2. 1126. Effect of Remdesivir on Recovery, Quality of Life, and Long-COVID Symptoms One Year after Hospitalization for COVID-19 Infection: A Randomized Controlled SOLIDARITY Finland Trial2022 · randomised trial · 208 randomised · 181 analysed
    Summary

    This open-label randomized multicenter trial in Finland asked whether adding remdesivir to standard of care improved one-year outcomes after hospitalization for COVID-19. Between July 2020 and January 2021, 208 adult patients from 11 Finnish hospitals were randomly assigned to standard of care with remdesivir (median duration of remdesivir treatment 5 days) or standard of care alone; 114 were in the remdesivir group and 94 in the SoC group. At one year, 5 (4.4%) of 114 patients in the remdesivir group and 5 (5.3%) of 94 in the SoC group had died (RR 0.82, 95% CI 0.25-2.76; absolute difference -0.9%, 95% CI -7.9-5.3). Self-reported recovery (fully or largely) occurred in 85% with remdesivir and 86% with SoC (RR 0.94, 0.47-1.90; absolute difference -0.9%, 95% CI -11%-10%). Exertional dyspnea occurred in 5% with remdesivir and 8% with SoC (OR 0.61, 95% CI 0.20-1.85; absolute difference -3.3%, 95% CI -12%-4.4%). The authors found no convincing difference between groups in quality of life or symptom outcomes (p > 0.05 for all). Among potential long-COVID symptoms, patients often reported moderate or major bother from fatigue (26%), joint pain (22%), persistent respiratory mucus (21%), problems with memory (19%), and attention/concentration (18%). 181 (92% of survivors) completed follow-up. Side-effect counts and withdrawals were not reported. The authors state confidence intervals were wide and included possible substantial benefit and substantial harm.

  3. Pharmacological prevention of post-COVID syndrome in real-world clinical practice: results of a 36-month prospective cohort study2026 · compared with another group · 221 in the study · 159 with outcome data
    Summary

    This prospective observational cohort study examined drugs used in acute COVID-19 and early post-acute care for later post-COVID syndrome. It enrolled 221 adults hospitalized with COVID-19 pneumonia at Kharkiv City Clinical Hospital No 13. Groups were compared without randomisation. Drugs were dexamethasone 6 мг/добу throughout hospitalization; methylprednisolone 500 мг/добу for 3 днів; remdesivir 200 мг then 100 мг/добу for 5 — 10 діб; antibiotics; edaravone 60 мг/добу for 10 днів; and quercetin 80 мг and L-arginine 1000 мг three times daily, or spironolactone 50 мг/добу for the first month after discharge. Outcomes were exercise-tolerance recovery at 1 month and absence of PCS symptoms at 3, 12 and 36 months. 159 patients completed 36 months; 62 were lost to follow-up. No statistically significant risk reduction was reported at any stage for methylprednisolone, antibiotics, remdesivir, quercetin, or L-arginine. Dexamethasone: significant reduction at 3 months (RR 0,67; NNT = 2,86), RR 0,62 and 1,10 at 12 and 36 months without significance. Edaravone: reduction at 1 month (RR 0,27; NNT = 4,36) that lost significance later. Spironolactone: no significant effect at 1 and 3 months (RR 0,63 and 0,99); significant reductions at 12 months (RR 0,38; NNT = 3,51) and 36 months (RR 0,53; NNT = 4,78); adjusted 12-month RR 0,30 (95 % CI 0,14 — 0,66). L-arginine at 1 month: RR 0,29 (p = 0,051). At 36 months, antibiotics and methylprednisolone had non-significant increased RR to 1,93 and 1,53. No harms data and no withdrawals for harms were reported in the recorded data.

  4. Risk of Long COVID in hospitalized individuals treated with remdesivir for acute COVID-19.2025 · compared with another group · 52,006 in the study
    Summary

    This retrospective cohort study used the HealthVerity database to ask whether remdesivir during acute COVID-19 was associated with later Long COVID in patients aged ≥12 years hospitalized for ≥2 days with COVID-19 between May 1, 2020, and September 30, 2021. Of 52,006 included patients, 17,164 were remdesivir-exposed (≥1 dose on Day 0 or Day 1) and 34,842 were unexposed (no remdesivir during the first 2 days). Outcomes were assessed 90–270 days after hospital admission. For the composite primary outcome of any Long COVID outcome, the risk ratio was 0.96 (95% CI 0.94–0.97; P <0.001), reported as a lower risk with remdesivir. The paper also reported lower risk for neuropsychiatric features, cognitive dysfunction, chest pain, cerebrovascular disease, thromboembolic disease, ischemic heart disease, diarrhea, headache, and dysautonomia after weighting and correction for multiple testing. In immunocompromising subgroups, it reported reduced risk of cognitive dysfunction, chest pain, cerebrovascular disease, and diarrhea; in the moderately-to-severely immunocompromised subgroup, reduced risk of diarrhea. Results for all other outcomes were nonsignificant, and none indicated increased risk associated with remdesivir. The paper did not report harms or withdrawals. Authors state limitations including early-pandemic data and limited generalizability, unavailable vaccination status, possible residual confounding by severity, and possible under- or overestimation of Long COVID outcomes.

  5. Intravenous Administration of Remdesivir at the Acute Phase of SARS-CoV-2 Infection Is Associated with a Lower Prevalence of Post-COVID-19 Pain.2025 · compared with another group · 300 in the study · 216 with outcome data
    Summary

    The study asked whether intravenous Remdesivir given during hospitalization for acute SARS-CoV-2 infection was associated with less post-COVID-19 pain in previously hospitalized COVID-19 survivors from four urban hospitals in Madrid, Spain. Of 300 invited patients who received Remdesivir, 216 agreed; a matched cohort of 216 patients who received no antiviral treatment was also included. Remdesivir was given intravenously as 200 mg on the first day, then 100 mg per day for five consecutive days or until discharge if hospitalization was shorter than five days, with a maximum of 10 days. Patients were assessed about pain after hospitalization: 18.3 months (SD 0.7) in the Remdesivir group and 18.4 months (SD 1.0) in the no-antiviral group. At the time of the study, post-COVID-19 pain prevalence was 22.7% (n = 49) with Remdesivir and 39.8% (n = 86) without antiviral treatment (OR 0.444, 95% CI 0.292–0.674, p < 0.001). Pain locations were similar overall, but thorax/chest pain (OR 0.277, 95% CI 0.100–0.766, p = 0.01) and lumbar spine pain (OR 0.347, 95% CI 0.143–0.844, p = 0.02) were lower with Remdesivir. Anxiety (n = 70, 32.4% vs n = 4, 1.85%) and depressive symptoms (n = 80, 37.05% vs n = 7, 3.2%) were higher without antiviral treatment; poor sleep did not differ (n = 77, 35.6% vs n = 76, 35.3%). Harms were not reported. The authors state the findings apply only to previously hospitalized survivors.

  6. Remdesivir and risk of long-term multi-systemic sequelae following COVID-19 hospitalization.2025 · compared with another group · 46 in the study · 30 started · 30 with outcome data
    Summary

    This retrospective population-based cohort used Singapore's national COVID-19 testing registry to study adult Singaporeans hospitalized for COVID-19 from September 1, 2021, to July 31, 2023. Of 46 843 individuals hospitalized, 30 175 fulfilled inclusion criteria. The study compared 11 353 people who received intravenous remdesivir with 18 822 controls not treated with remdesivir; 96.6% (10 966/11 353) received remdesivir within 24 hours of admission, and a standard duration of 5 days was recommended. It assessed new-incident cardiovascular, neurological, respiratory, and autoimmune diagnoses and persistent symptoms from 31 to 300 days post-hospitalization; mean follow-up was 241.0 days in remdesivir recipients and 256.9 days in untreated individuals. For any long-term diagnosis, the adjusted hazard ratio was 1.08 (95% CI, 0.97—1.20; p 0.147), reported as not significantly different. The abstract states no significant difference in long-term symptom persistence at 300 days. Other neurological disorders had aHR 0.72 (95% CI, 0.55—0.94; p 0.017), but this did not cross the multiple-comparison threshold; ARR was 3.68 (95% CI, -0.51 to 7.87). In a subgroup with mild comorbidity burden, sensory disorders had aHR 0.49 (95% CI, 0.29—0.80; p 0.002) and ARR 4.66 (95% CI, 0.45—8.88). The negative-control solid-organ malignancy aHR was 0.92 (95% CI, 0.71—1.21; p 0.561). No harms, adverse events, or discontinuation for harms are reported in the text. The text does not report worsening counts. Limitations include unmeasured confounders and unavailable laboratory parameters.

  7. Association of COVID vaccinations and treatments with long COVID beyond 6 months: a case-control study on the adult population in a large integrated healthcare system in the United States from 2020 to 2023.2025 · compared with another group · 840 with outcome data
    Summary

    This case-control study used electronic medical records from Kaiser Permanente Southern California to examine whether COVID vaccination or acute COVID treatments were associated with Long COVID at least 6 months after infection. Adults with Long COVID diagnosed by ICD-10 code were matched to controls without Long COVID by age, sex, race/ethnicity, body mass index, and date of acute COVID infection. The January 2022 to June 2023 analysis included 840 cases and 4200 controls; the October 2020 to June 2023 analysis included 2632 cases and 13,160 controls. Patients with a history of ME/CFS or fibromyalgia fulfilling ME/CFS criteria were excluded. Compared with no vaccination, one dose was associated with lower odds of Long COVID (OR 0.77; 95 % CI 0.63–0.96), two doses (OR 0.73; 95 % CI 0.59–0.92), three doses (OR 0.66; 95 % CI 0.44–1.00), and four doses (OR 0.29; 95 % CI 0.06–1.49). Nirmatrelvir/ritonavir was associated with lower odds (OR 0.05; 95 % CI 0.04–0.07), as was remdesivir (OR 0.31; 95 % CI 0.19–0.49). No interaction was found between nirmatrelvir/ritonavir and one, two, or three vaccinations (p = 0.38, p = 0.24, p = 0.08); an interaction was found with four doses (p = 0.002). No interaction was found between remdesivir and one to four vaccinations (p = 0.74, p = 0.92, p = 0.96, p = 0.98). No harms or withdrawals were reported. The authors state the case-control design cannot establish causality and note possible misclassification of the index infection and limited power.

  8. P-2363. Efficacy Of SARS–CoV-2 Specific Antiviral Therapy for Enteroviral Myalgic Encephalomyelitis/ChronicFatigue Syndrome2025 · compared with another group
    Summary

    This abstract reports a study of patients with ME/CFS who fulfilled Canadian consensus criteria and had elevated neutralizing antibody for enteroviruses and/or positive enterovirus protein in peripheral blood leukocytes. Patients hospitalized for acute COV19 and non-COV19 patients were given IV remdesivir for 5-10 days with or without immune modulators; other non-COV19 ME/CFS patients were given nirmatrelvir/ritonavir daily for 10 days with or without one repeat. Twenty concurrent ME/CFS patients without remdesivir served as controls. Patients monitored an energy index. Among remdesivir-treated patients, 15/20 (75%) responded 2-6 weeks after infusions, including 10/12 hospitalized and 5/8 non-COV19 patients; remission lasted 6-8 weeks to 6-9 months before relapse. Controls: 2/20 had mild improvement (<0.001, X 2 ). Of PAX-treated patients, 104/200 (52%) improved, often within 2-3 days; all relapsed within days to weeks after treatment. Response was 66% in CVB4+, 33% in CVB3+, and 44% in non-CVB3,4+ patients. Side effects were not described, and the paper did not report withdrawals in connection with harms. The authors state that remdesivir and PAX demonstrated clinical efficacy and that placebo-controlled RCTs are needed.

  9. Real-world evidence of remdesivir in formerly hospitalized COVID-19 patients: patient-reported and functional outcomes.2025 · compared with another group · 293 in the study · 94 with outcome data
    Summary

    This 2-year observational cohort study used a prospective single-center registry of formerly hospitalized COVID-19 patients (N = 293) presenting to a post-COVID outpatient clinic in Budapest, Hungary. After propensity score matching, 94 patients who received remdesivir in addition to standard-of-care (SOC + RDV) were compared with 94 patients who received SOC only. Remdesivir duration and route were not reported. Primary outcomes were asymptomatic status and at least 50% symptom score reduction at post-COVID follow-up; secondary outcomes included pulmonary function, 6-minute walk test and quality-of-life questionnaires. RDV was associated with earlier asymptomatic status (adjusted HR = 2.28, 95% CI = 1.33–3.92, p = 0.003) and earlier at least 50% symptom burden reduction (adjusted HR = 2.08, 95% CI = 1.43–3.02, p < 0.001). At 6 months, asymptomatic patients were 36 (38.3) vs 23 (24.5), p = 0.041, and at least 50% symptom score reduction was 67 (71.3) vs 40 (42.6), p < 0.001. Symptomatic patients at first visit were 60% vs 66%, p = 0.449. Sleep disturbances were 14% vs 27%, p = 0.0029; PSQI scores were 5.90 vs 7.66, p = 0.025. ESS, PF tests, 6MWT and other QoL questionnaires showed no differences. Side effects and withdrawals were not reported.

  10. Better post-acute sequelae COVID19 observed in hospitalized COVID19 patients treated with remdesivir2024 · compared with another group · 293 in the study
    Summary

    This study looked at post-acute sequelae COVID19 (PASC) in former inpatients presenting to post-COVID pulmonary care. The paper categorized N=293 patients by whether they received remdesivir (RDV; N=183) or only standard of care (SOC; N=110); randomisation, dose, schedule and follow-up duration were not reported. Patients were assessed for symptoms during and after COVID19, pulmonary functions (PF), 6-minute walk test (6MWT) and quality of life (QoL). Length of hospital stay was significantly shorter in the RDV group (14±13 vs. 19±19 days, p=0.022). PASC symptom profile between the groups did not confirm differences, but sleep disturbances disappeared in a higher proportion in the RDV group and ≥50% reduction in symptoms was more common among RDV-treated patients. PF and 6MWT parameters were similar, while patient-reported QoL was significantly better in the RDV group. Side effects and withdrawals were not reported. The authors conclude that patients treated with RDV spent less time in hospital and had more often at least 50% improvement in symptom profile at PASC, indicating that this antiviral therapy might have a long-term beneficial effect on QoL.

  11. Is Antiviral Treatment with Remdesivir at the Acute Phase of SARS-CoV-2 Infection Effective for Decreasing the Risk of Long-Lasting Post-COVID Symptoms?2024 · compared with another group
    Summary

    This case-control study asked whether intravenous Remdesivir given during acute COVID-19 hospitalization was associated with fewer long-lasting post-COVID symptoms. It included 216 previously hospitalized COVID-19 survivors who received Remdesivir (200 mg the first day and 100 mg/day for 5 consecutive days or until discharge, if shorter than 5 days, for a maximum duration of 10 days) and 216 matched survivors who did not receive Remdesivir. Participants were assessed at 18.3 (SD 0.7) months after discharge in the Remdesivir group and 18.4 (SD 1.0) months in the no-Remdesivir group. At the time of the study, 141 (65.3%) Remdesivir patients reported at least one post-COVID symptom versus 178 (82.4%) in the no-Remdesivir group (OR 0.401, 95%CI 0.256 to 0.628, p < 0.001). The Remdesivir group reported a lower number of post-COVID symptoms (mean 1.6, SD 1.6) than the no-Remdesivir group (mean 2.1, SD 1.4; p = 0.02). The multivariate analysis reported Remdesivir as a protective factor for fatigue, pain, dyspnea at rest, memory loss, concentration loss, hair loss and skin rashes, and lower FIC symptoms, FIC disability, HADS-A and HADS-D scores. Harms and withdrawals were not reported. The authors state limitations including only hospitalized cohorts.

  12. LESS POST-COVID SYMPTOMS AMONG REMDESIVIR-TREATED PATIENTS2023 · compared with another group · 386 in the study · 267 started · 267 with outcome data
    Summary

    This retrospective study enrolled patients in post-COVID care at the Department of Pulmonology at Semmelweis University between 01/02/2021-30/06/2022. Out of 386 patients, 267 were previously hospitalized; they were categorized by whether they received standard of care (SOC; N=99) or additional remdesivir (RDV; N=168). The study evaluated remdesivir in post-COVID symptoms after hospitalization for COVID-19. Post-COVID care included detailed lung function test, 6-minute walk test (6MWT) and visual analogue scale (VAS). Length of hospital stay was 18.8 15.7 vs. 14.4 12.8 days in groups respectively (p=0.01). RDV treated patients applied earlier at post-COVID care (average 125.2 133.2 vs 78.2 82.2 days, p=0.002). Post-COVID symptoms reported were respiratory (43.4 vs 28.0%, p<0.01), fatigue (58.6 vs 28.6%, p<0.01) and sleep disorders (40.4 vs. 13.1%, p<0.01). There was no significant difference in functionality (lung function and 6MWT parameters) between the groups. RDV-treated group reported significantly better patient-reported outcomes by VAS (71.1 19.1 vs. 75.7 16.0; p=0.05). The text does not report side effects or withdrawals. The text does not state limitations.

  13. Treatment of COVID-19 during the Acute Phase in Hospitalized Patients Decreases Post-Acute Sequelae of COVID-19.2023 · compared with another group · 2,716 in the study · 1,966 started · 1,966 with outcome data
    Summary

    This single-center prospective observational study asked whether treatments given during acute COVID-19 were associated with post-acute sequelae of SARS-CoV-2 (PASC). The cohort included 2716 subjects referred after hospitalization or from primary care; 416 died and 334 were lost during follow-up and were excluded, and 1966 patients were followed at a Post-COVID-19 Unit. Hospitalized patients received protocolized remdesivir (200 mg the first day and 100 mg/day for 5 days), dexamethasone (6 mg/day for 10 days), tocilizumab in worsening respiratory symptoms, or methylprednisolone for organizing pneumonia; outpatients received no therapy. Treatment groups were compared with patients not receiving each treatment, with duration of PASC symptoms measured. In moderate disease, remdesivir was associated with 109 vs. 262 days and in severe disease 187 vs. 284 days, reported as significantly shorter. Dexamethasone showed 133 vs. 271 days in moderate and 266 vs. 309 days in severe disease; significance was not reported in the recorded result. Tocilizumab and methylprednisolone were not associated with a reduction in duration of PASC symptoms. Harms and withdrawals due to harms were not reported. The authors state limitations including no control group, single-center early-pandemic data, no vaccination status, and possible overestimation from nonparticipants having milder symptoms.

  14. Modifiable in-hospital factors for 12-month global cognition, post-traumatic stress disorder symptoms, and depression symptoms in adults hospitalized with COVID-19.2023 · compared with another group · 479 in the study · 203 with outcome data
    Summary

    In this ancillary analysis of the ORCHID trial, adults hospitalized with acute COVID-19 at 34 US hospitals were assessed at 12 months; 479 were enrolled in the parent trial and 203 contributed to this analysis. Hydroxychloroquine was received by 97 (47.8%), corticosteroids by 29 (14.3%), and remdesivir by 45 (22.2%). The study compared receipt of these in-hospital medications (any dose versus no dose) and reported adjusted odds ratios for 12-month cognition, PTSD, and depression. Remdesivir use was associated with higher MOCA-Blind global cognition (aOR 1.98, 95% CI 1.06, 3.70) and higher WAIS Similarities scores (aOR 2.40, 95% CI 1.23, 4.69). No significant association was observed for remdesivir and the Cognitive Composite Score (aOR 1.57, 95% CI 0.84, 2.94). Corticosteroid use was associated with lower WAIS Similarities scores (aOR 0.42, 95% CI 0.19, 0.90). There was no association between 12-month global cognition and hydroxychloroquine or corticosteroids, and hydroxychloroquine did not improve any 12-month cognitive or psychological outcomes. Harms, side effects, and withdrawals for harms were not reported.

  15. Formerly hospitalized patients treated with remdesivir presented less respiratory post-COVID symptoms2023 · compared with another group · 267 in the study
    Summary

    Post-COVID syndrome is described as a not well-defined condition, and associated patient characteristics were under investigation. This study enrolled patients formerly hospitalized at the Department of Pulmonology, Semmelweis University who presented at post-COVID care (N=267). Patients were divided by receiving remdesivir (RDV; N=168) or standard of care (SOC; N=99). Treatment duration was not reported. At post-COVID care, assessments included patient characteristics, therapy, visual analogue scale (VAS), detailed lung function and 6-minute walk test (6MWT). RDV-treated patients spent less time in hospital (14±13 vs 19±16 days, p=0.01). Patients on SOC attended post-COVID care later following infection (172±111 vs 217±147 days, p<0.01). At post-COVID care, patients on SOC had more symptoms, including respiratory (28 vs 43%, p<0.01), fatigue (29 vs 59%, p<0.01) and sleep disorders (13 vs 40%, p<0.01). Lung function and 6MWT values did not differ. VAS was less frequently below the Hungarian average in RDV-treated patients (20 vs 31%, p=0.03). The abstract does not report harms, withdrawals, or limitations.

  16. 519. Early Transition to Outpatient Remdesivir Increases Patient Satisfaction while Decreasing Hospital Costs2023 · compared with another group · 3,029 in the study
    Summary

    This study at Mayo Clinic, Rochester, MN, assessed patient perspectives and the economic impact of continuing remdesivir outside the hospital. During a one-year period, 3,029 patients received remdesivir for COVID-19 in the hospital; 542 were dismissed to continue remdesivir in the outpatient setting and were surveyed, and 470 of 542 patients were surveyed. Of these, 93 (19.8%) responded; responders were older than non-responders (median, 63 vs. 58 years). The remdesivir course was 5 days. The cost of care was compared between patients who remained in the hospital and those dismissed to outpatient remdesivir. Among responders, 70.5% had symptoms resolved by the time of the survey, and ten patients (11.4%) had persistent symptoms attributed to long COVID-19. For the outpatient program, 73.8% were excited to learn about it; 81.0% felt receiving therapy at home was the right decision; 79.5% had support and felt the benefits of completing treatment at home. Satisfaction was 75.6% with communication before and 80.5% during the outpatient appointment, 80.3% with information on benefits, 58.5% with risks, 88.6% with time at the infusion center, 82.3% with quality of care and 76.0% with overall experience. Benefits were high-value for 82.6%. After adjusting for gender, comorbidity score, and WHO scale, predicted costs were $16,544 (inpatient) and $9,097 (outpatient) per patient (difference of $7,447; p< .01), and an estimated total of 1,077 hospital room-days were made available to other patients. Harms and withdrawals for harms were not reported.

  17. 392. The Impact of Therapeutic Interventions on Post-Acute Sequelae of SARS-CoV-2 (PASC) in COVID-19 Survivors: A Retrospective Analysis2023 · compared with another group
    Summary

    Researchers conducted a retrospective chart review at the reCOVer Clinic at Cleveland Clinic Foundation from March 2020 to November 2022. The paper defines PASC as persistent and debilitating symptoms continuing more than 28 days beyond the acute phase of COVID-19. They identified 57 patients deemed to have PASC and matched them with controls without PASC at a 1:1 ratio. The study reviewed multiple interventions given at the time of COVID-19 diagnosis; treatment duration was not reported. Among those who received nirmatrelvir-ritonavir, tocilizumab, remdesivir and dexamethasone, the paper reports no statistical differences in those that eventually developed PASC (p-values of 0.50, 0.74, 0.07 and 0.06, respectively). No harms or side effects are reported. The authors conclude that treatment alone at the time of COVID-19 diagnosis is not protective against the development of PASC and state that further studies are needed to identify other potential risk factors for PASC.

  18. Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect?2022 · compared with another group · 462 in the study · 449 started · 449 with outcome data
    Summary

    This prospective study asked whether remdesivir during hospitalization for COVID-19 was associated with long-COVID syndrome (LCS) in patients followed after discharge at a single infectious diseases centre in Vercelli, Italy. Of 462 patients discharged after COVID-19 admission, 13 were not included, and 449 were included in the analysis; 435 were included at Visit 2. Patients were followed for at least 6 months, with Visit 1 and Visit 2 at about 30 and 180 days after discharge. In the cohort, 163 patients received remdesivir and 165 received no antiviral treatment. LCS was diagnosed in 322 patients at Visit 1 (71.7%) and 206 at Visit 2 (45.9). On the PCFS scale, 147 patients had values 2–3 and 175 had values >3 at Visit 1; at Visit 2, 133 had scores 2–3 and 73 >3. In multivariate analysis, treatment with remdesivir had OR 0.641 (95% CI 0.413–0.782; P < 0.001) for LCS. The authors report a 35.9% reduction in LCS rate in follow-up. At Visit 1, 123 patients receiving remdesivir were not affected by LCS versus 81 without remdesivir; PCFS scores 2–3 were 27 versus 120, and scores >3 were 13 versus 85 (P < 0.001). Survival analysis comparing remdesivir-treated and control patients for LCS diagnosis showed v2 = 14.614, P < 0.001. Harms were not reported. Between Visits 1 and 2, 14 patients (3.1%) were excluded: 2 died, 8 were lost to follow-up, and 4 were re-hospitalized.

  19. An open-label feasibility study of remdesivir in long COVID: results from the ERASE LC trial.2026 · no comparison group · 73 in the study · 70 with outcome data
    Summary

    This two-centre (Derby and Exeter, UK) open-label, single-arm feasibility trial assessed a five-day intravenous remdesivir regimen in 73 adults with long COVID. Remdesivir was given as a 200 mg loading dose on day 1 and 100 mg on days 2–5, with no comparator group. Feasibility outcomes included recruitment, treatment completion, follow-up completion and assessment completeness; exploratory outcomes included patient-reported measures and clinical assessments. Of 73 enrolled, 71 (97%) completed the full 5-day IV remdesivir regimen and 70 (96%) completed post-intervention assessments. There was one serious adverse event, assessed as unrelated to the intervention; 47 adverse reactions occurred in 22 participants (31%), none severe. One participant withdrew after day 2 of treatment due to an adverse reaction. Mean (SD) FAS total score was 34.3 (7.3) at baseline compared with 28.3 (8.0) post-intervention, and 53 (78%) participants had a reduction in FAS total score; 12 (17%) demonstrated worsening fatigue scores. Mean (SD) 6MWT distance was 408 (113) metres at baseline compared with 468 (109) metres post-intervention. The authors state the trial was not designed to evaluate clinical efficacy.

  20. An Open-Label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long COVID – ERASE LC2026 · no comparison group · 73 in the study
    Summary

    This open-label clinical feasibility study asked whether a five-day intravenous remdesivir course is feasible for Long COVID. Seventy-three participants aged ≥18 years with a confirmed Long COVID diagnosis were recruited across two sites in the United Kingdom. Participants were recruited to receive a five-day course of IV remdesivir; there was no comparison group. The study collected patient-reported outcomes (e.g. fatigue assessment scale [FAS]) and clinical outcomes (e.g. 6-minute walking test [6MWT]). Seventy-three participants were recruited, and 71 (97%) completed the treatment regimen. Forty-seven adverse reactions were reported from 22 (31%) participants; none were classified as being severe. The abstract also states that clinically important changes were reported in several clinical assessments and patient-reported secondary outcomes, without giving details. The authors conclude that they demonstrate feasibility and acceptability of administering IV remdesivir in people with mild to moderate LC. They state that rigorous evaluation in randomised controlled trials is essential to determine the true efficacy and clinical utility of intravenous remdesivir in this population.

  21. Long COVID: A Systematic Review of Preventive Strategies.2025 · systematic review
    Summary

    This systematic review asked whether treatments can prevent long COVID, defined as symptoms lasting three or more months after SARS-CoV-2 infection. The authors searched PubMed/MEDLINE for articles published between December 2019 and September 2024 and included 28 studies: fifteen on COVID-19 vaccination, seven on antivirals, and six on other treatments. Findings are reported study by study rather than pooled. For vaccination, ten out of fifteen studies demonstrated a protective effect against long COVID; Ayoubkhani et al. reported odds decreased by 12.8% after a first dose and by an additional 8.8% after a second dose compared with unvaccinated individuals, while Antonelli et al. found a booster did not reduce risk when long COVID was defined as symptoms lasting 12 weeks or longer. For antivirals, a randomized trial of remdesivir found no significant differences between treated and untreated groups, whereas Boglione et al. reported a 36% reduction in odds with remdesivir and Wang et al. reported nirmatrelvir/ritonavir reduced odds by 65%. Convalescent plasma showed no statistically significant reduction; metformin showed a 42% reduction in long COVID incidence; multiple micronutrient supplements for 2 weeks showed no differences. Luo et al. reported vaccination after infection increased risk of reporting long COVID symptoms, which may be due to side effects. No stopping data were recorded. The authors state that COVID-19 vaccines likely reduce the risk of developing long COVID, while evidence for antivirals and other drugs is still in its infancy.

  22. Preventive interventions for post Covid-19 condition: systematic review update2024 · systematic review · preprint
    Summary

    This systematic review update searched on February 9, 2024 and included 24 studies (5 randomized and 19 non-randomized), all among adults. It examined interventions given during acute or post-acute COVID-19 to prevent post COVID-19 condition (PCC). For convalescent plasma in outpatients (1 trial; N=882), the RR (95% CI) was 0.93 (0.77-1.12), with moderate certainty. For probiotics in outpatients (1 trial; N=69), RR was 0.32 (0.13-0.78), low certainty. For metformin in outpatients (1 trial; N=450), RR was 0.50 (0.25-0.99), low certainty. For ivermectin in outpatients (1 trial; N=374), RR was 0.93 (0.50-1.71), low certainty. Therapeutic-dose heparin versus prophylactic-dose heparin in inpatients (1 trial; N=571) had RR 1.11 (0.94-1.30) for PCC, low certainty; for cognitive impairment RR was 0.49 (0.22 to 1.07), low certainty; and for HRQoL the MD was 0.12 (-3.22 to 3.46) [range 0-100], moderate certainty. In one trial, metformin (n=569) had no serious adverse events per group; fluvoxamine (n=319), ivermectin (n=406), metformin and fluvoxamine (n=336), and metformin and ivermectin (n=401) had no events in any comparison.

  23. Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review.2024 · systematic review
    Summary

    This systematic review asked whether medicines given during acute SARS-CoV-2 infection reduce the risk of long-COVID. The authors searched MEDLINE, CINAHL, PubMed, EMBASE, Web of Science, medRxiv and bioRxiv up to July 15th, 2023. From 517 studies identified, 6 peer-reviewed studies and one preprint met inclusion criteria. The sample included 2683 (n = 4) hospitalized COVID-19 survivors and 307,409 (n = 3) non-hospitalized patients. The review compared people who received a specific medication during the acute phase with those who did not; treatment duration was not reported. Two studies of Nirmatrelvir/Ritonavir and three studies of Remdesivir reported conflicting results on preventing long-COVID. Three studies of other medication, Dexamethasone (n = 2) or Metformin (n = 1), found positive results for preventing long-COVID. The authors describe the antiviral evidence as conflicting and heterogeneous, suggesting Remdesivir or Nirmatrelvir/Ritonavir could have a potential protective effect. They state that a limited number of studies showed a potential benefit of Dexamethasone or Metformin, but more studies are needed. No side-effect counts, withdrawals, or worsening events were reported in the recorded data. The authors state: “Available evidence about the effect of medication treatment with antivirals during acute COVID-19 and reduced risk of developing long-COVID is conflicting.”

  24. Experimental drugs in randomized controlled trials for long-COVID: what's in the pipeline? A systematic and critical review.2023 · systematic review
    Summary

    This systematic and critical review asked whether experimental drugs for long-COVID have been tested in randomized controlled trials, searching three databases on 21st March 2023. It included 4 completed and 22 ongoing trials. The completed trials came from Brazil, Russia, the U.S., and Finland. In Barros et al. (2021), 118 hospitalized COVID-19 patients received methylprednisolone or placebo; at day-120, FVC was 3.2 ± 0.8 vs. 2.9 ± 0.8 (P = .01), with no changes in 6MWD, functional capacity by DASI, or other lung functions. Bazdyrev et al. (2022) gave Treamid or placebo to 60 survivors with fibrotic lung changes; at week-4, FVC and DLCO increased (41% vs. 17%, P < .05) and Borg dyspnea decreased (−0.9 ± 0.7 vs. −0.4 ± 0.8, P < .05), but 6MWD, mMRC dyspnea, CT score, KBILD, and other pulmonary function showed no improvement; frequency of adverse events was unchanged. Bramante et al. (2022) randomized 1,125 COVID-19 patients with overweight or obesity: metformin lowered long-COVID diagnosis (6.3% vs. 10.6%) and risk (HR = 0.58, 95% CI 0.38–0.88) at day-300; ivermectin and fluvoxamine showed no changes. Nevalainen et al. (2022) randomized 181 hospitalized patients to remdesivir or standard care; at year-1 there were no changes in recovery, quality of life, or long-COVID symptoms.

  25. Therapeutic options for the treatment of post-acute sequelae of COVID-19: a scoping review.2025 · review
    Summary

    This scoping review asked which therapeutic agents can be used for post-acute sequelae of COVID-19 (PASC). The authors searched PubMed, Embase, and the Cochrane library for English studies published between January 1, 2020, and July 22, 2024; 413 studies were identified and 39 were included. The review did not report a total number of participants. Included reports measured symptoms such as fatigue, pain, cognitive function, olfactory function, pulmonary function, PASC incidence, hospitalization, and death. For metformin, among 1126 patients observed for nine months, 93 (9.3%) reported PASC, with a hazard ratio of 0.59 (95% CI 0.39–0.89; p = 0.012). Low-dose naltrexone showed a hazard ratio of 5.04 for improvement versus physical therapy alone among 108 patients (p = 0.02), and 52–67% of patients in observational studies reported improvements. In a randomized study of 30 patients with PASC and lung fibrosis, nintedanib and pirfenidone improved pulmonary function, 6MWT distance, and oxygen saturation over 12 weeks; nintedanib was associated with diarrhea (80%) and nausea/vomiting (66.6%). The STOP-PASC trial of a 15-day NMV-r course failed to show significant benefit. Ivermectin had no effect on PASC incidence in COVID-OUT, and remdesivir randomized trials showed no clear long-term benefit. The authors state limitations include heterogeneity of PASC symptoms and limited robust evidence.

  26. Treatable traits for long COVID.2023 · review
    Summary

    This comprehensive review asked how a treatable traits approach could be applied to long COVID. It combined an umbrella review of 22 systematic reviews identifying long COVID symptoms and complications with a systematic review of 18 randomized controlled trials of prevention or management. The trials tested many interventions, including metformin for 14 days during acute COVID-19 versus placebo, hyperbaric oxygen therapy versus sham, exercise training or respiratory muscle training versus usual care or sham, HD-tDCS versus sham, L-arginine plus liposomal vitamin C versus placebo, aromatherapy versus inert oils, and platelet-rich plasma injections versus saline. Outcomes included long COVID incidence, cognition, olfaction, dyspnoea, fatigue, exercise capacity and health-related quality of life. In one prevention trial, metformin was associated with reduced long COVID incidence at 10 months (hazard ratio 0.58 [95% CI 0.38, 0.88]) among 564 metformin and 561 placebo participants; ivermectin and fluvoxamine showed no significant benefit. For management, hyperbaric oxygen improved cognition compared with sham (104.1 ± 7.2 versus 101.3 ± 8.9, p = 0.038), and exercise training improved exercise capacity compared with exercise advice (38.9 ± 10.8 versus 36.1 ± 9.5 mL/kg/min, p = 0.035). Some studies found no significant between-group differences, including a larger exercise trial. Adverse events included 13 during hyperbaric oxygen versus 14 during control; one aromatherapy participant withdrew on day 13 with headaches, and one sham IMT participant withdrew for symptom exacerbation. The authors state the review was limited by not conducting a meta-analysis and by heterogeneity of the included systematic reviews.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime